| 16-377 |
A Multicenter, Open-label, Phase 1B Clinical Study of CMP-001 in combination with Pembrolizumab in Subjects with Advanced Melanoma (View details on clinicaltrial.gov) |
Phase I |
| 17-607 |
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (View details on clinicaltrial.gov) |
Phase I |
| 17-188 |
A Phase 1 Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients with Advanced Solid Tumors (View details on clinicaltrial.gov) |
Phase I |
| 16-456 |
A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination with Other Agents in Advanced Cancer (View details on clinicaltrial.gov) |
Phase I |
| 16-510 |
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A
Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients
with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose
Vasculature Expresses B7-H3 (View details on clinicaltrial.gov) |
Phase I |
| 16-611 |
A Phase 1, Open-Label, Dose-Finding and Cohort Expansion Study of ASN003 in Subjects with
Advanced Solid Tumors (View details on clinicaltrial.gov) |
Phase I |
| 17-330 |
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors (View details on clinicaltrial.gov) |
Phase I |
| 17-334 |
A Phase 1, Open-Label, Multicenter, Dose Escalation Study or MRNA-2416, A Lipid Nanoparticle Encapsulated MRNA Encoding Human OX4OL, For Intratumoral Injection to Patients with Advanced Malignancies (View details on clinicaltrial.gov) |
Phase I |
| 17-288 |
A Phase 1/1b first-in-human dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics and anti-tumor activity of SAR439459 administered intravenously as monotherapy and in combination with REGN2810 in adult patients with advanced solid tumors (View details on clinicaltrial.gov) |
Phase I |
| 16-586 |
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors (View details on clinicaltrial.gov) |
Phase II |
| 16-399 |
A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed
Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors (View details on clinicaltrial.gov) |
Phase II |
| 15-322 |
A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer and Melanoma (View details on clinicaltrial.gov) |
Phase II |
| 14-332 |
A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and
Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma (View details on clinicaltrial.gov) |
Phase II |
| 16-220 |
A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), In Patients with Advanced Cutaneous Squamous Cell Carcinoma (View details on clinicaltrial.gov) |
Phase II |
| 12-487 |
A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors (View details on clinicaltrial.gov) |
Phase I |
| 12-306 |
A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients (View details on clinicaltrial.gov) |
Phase I |
| 16-274 |
A Phase I, open label, multicenter study of the safety and efficacy of MIW815 (ADU-S100) administered by intratumoral injection to patients with advanced/metastatic solid tumors or lymphomas (View details on clinicaltrial.gov) |
Phase I |
| 15-012 |
A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, To Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations (View details on clinicaltrial.gov) |
Phase II |
| 17-269 |
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma (View details on clinicaltrial.gov) |
Phase II |
| 16-642 |
A phase II trial of abbreviated MAPK targeted therapy plus pembrolizumab in patients with unresectable or metastatic melanoma (View details on clinicaltrial.gov) |
Phase II |
| 16-212 |
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors (View details on clinicaltrial.gov) |
Phase II |
| 16-269 |
An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma (View details on clinicaltrial.gov) |
Phase I |
| 16-344 |
An Open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder (View details on clinicaltrial.gov) |
Phase I |
| 16-150 |
Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers (View details on clinicaltrial.gov) |
Phase I |
| 16-501 |
Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies (View details on clinicaltrial.gov) |
Phase II |
| 14-186 |
Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in BRAF-Inhibitor Resistant Patients With BRAF-Mutant Melanoma and Other Solid Tumors (View details on clinicaltrial.gov) |
Phase I |
| 17-383 |
Phase Ib Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma
(View details on clinicaltrial.gov) |
Phase I |